Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.34 |
| ▸ | LMNA | P02545 | 6/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23409337 | 0.88 | GRM5 (0.36) | MAPTKDM4ELMNAL3MBTL1MAPK1 | |
| SCHEMBL29903155 | 0.88 | GRM5 (0.36) | MAPTKDM4ELMNAL3MBTL1MAPK1 | |
| SCHEMBL25354760 | 0.86 | L3MBTL1 (0.34) | MAPTKDM4ELMNAL3MBTL1TDP1 | |
| SCHEMBL25354201 | 0.84 | CTNNB1 (0.35) | KDM4EL3MBTL1TDP1F2ELANE | |
| SCHEMBL30576965 | 0.84 | CTNNB1 (0.35) | KDM4EL3MBTL1TDP1F2ELANE | |
| SCHEMBL25428945 | 0.78 | CYP1A2 (0.44) | MAPTRAB9ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29903159 | 0.76 | CYP1A2 (0.35) | MAPTKDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL23409334 | 0.76 | CYP1A2 (0.35) | MAPTKDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL25824423 | 0.76 | HTR2A (0.33) | MAPTCYP1A2GRM5 | |
| SCHEMBL25353794 | 0.73 | CTNNB1 (0.34) | KDM4EL3MBTL1TDP1CTNNB1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | disclosed |
| EP-4476221-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023152255-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023152255-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | KRAS, NRAS, TP53 | MAPT 4220/4885KDM4E 2684/4885LMNA 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.